Amendments to the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application, wherein additions are shown in underlined text and deletions are shown in strike-out text:

Claims **1-40** (Cancelled).

Claim **41** (Currently Amended) A method of treating an individual suffering from fibromyalgia and other somatoform disorders, the method comprising the step of administering to the individual a therapeutically effective ~~dose~~ amount of racemic reboxetine or a pharmaceutically acceptable salt thereof ~~to an individual~~.

Claim **42** (Cancelled).

Claim **43** (Cancelled).

Claim **44** (Currently Amended) The method of claim **41** wherein ~~the~~ said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 2 to about 20 mg/day.

Claim **45** (Currently Amended) The method of claim **44** wherein ~~the~~ said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 4 to about 10 mg/day.

Claim **46** (Currently Amended) The method of claim **45** wherein ~~the~~ said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered to the individual in an amount of about 6 to about 10 mg/day.

Claim **47** (Currently Amended) The method of claim **41** wherein said racemic reboxetine, or a pharmaceutically acceptable salt thereof, is administered as a composition and said composition is administered orally, parenterally, topically, transdermally, rectally, or vaginally.

Claim **48** (Currently Amended) The method of claim **47** wherein said ~~reboxetine~~ composition is orally administered, and further comprising ~~with~~ a pharmaceutically acceptable carrier comprising at least one of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, and wetting agent.

Claim **49** (Original) The method of claim **48** wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **50** (Currently Amended) The method of claim **47** wherein said ~~reboxetine~~ composition is ~~parentarally~~ parenterally administered subcutaneously, ~~intravenously~~ intravenously, or intramuscularly.

Claim **51** (Original) The method of claim **41** wherein the pharmaceutically acceptable salt is methanesulfonate salt.

Claim **52** (Cancelled).

Claim **53** (Cancelled).

Claim **54** (New) The method of claim **41**, wherein the other somatoform disorders are selected from the group consisting of one or more of a somatization disorder, a conversion disorder, a pain disorder, hypochondriasis, a body dysmorphic disorder, an undifferentiated somatoform disorder, and somatoform NOS.